ProfileGDS5678 / 1437545_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 82% 81% 83% 82% 81% 81% 82% 82% 82% 82% 82% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.640280
GSM967853U87-EV human glioblastoma xenograft - Control 25.951282
GSM967854U87-EV human glioblastoma xenograft - Control 35.8684881
GSM967855U87-EV human glioblastoma xenograft - Control 46.1980783
GSM967856U87-EV human glioblastoma xenograft - Control 55.9062182
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6177381
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6692181
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9760182
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9246282
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0456582
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9754682
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0439182
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9140382
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9589782